Roche has recently solidified a partnership with Prenosis to distribute its AI sepsis detection tool, Sepsis ImmunoScore, across the United States. This diagnostic tool, which has received FDA De Novo authorization, marks an advancement in the battle against sepsis, a condition noted for its high mortality rate, accounting for one in every three hospital deaths annually and affecting an estimated 1.7 million American adults each year. Integrated into Roche’s Navify Algorithm Suite, the Sepsis ImmunoScore utilizes a sophisticated algorithm that evaluates up to 22 patient-specific parameters, including vital signs like respiratory rate and blood pressure, along with lab-based biomarkers such as Procalcitonin. This integration allows the algorithm to assess the likelihood of a patient developing sepsis within 24 hours, providing a timeframe for potential life-saving intervention. The inclusion of this tool in the Navify suite shows an effort to streamline access to validated medical algorithms, enhancing diagnostic precision and allowing timely medical responses.
The ongoing collaboration between Roche and Prenosis, which began in 2020 and expanded in 2021, has focused on making the Sepsis ImmunoScore widely available in the U.S. healthcare market. By incorporating this AI tool into the Navify Algorithm Suite—a platform launched in April 2023—Roche has broadened the utility of its diagnostic offerings and created a channel for healthcare providers to seamlessly integrate these advanced tools into existing workflows. This platform is designed to be embedded within existing medical record software and information systems, ensuring compliance with global data regulations and enhancing user accessibility. The suite features Roche’s clinically validated algorithms and is open to third-party software developers, offering a solution that covers various disease areas. This approach simplifies the integration process for healthcare facilities and enhances the functionality and appeal of the Navify platform, enabling more efficient decision-making and potentially transforming patient outcomes across multiple clinical settings.
The development of the Sepsis ImmunoScore by Prenosis is the result of extensive research and collaboration with multiple hospital systems over a decade, aimed at building the largest proprietary biobank and dataset for fast-moving immune responses in acute care settings. This dataset now includes over 100,000 blood samples from more than 25,000 patients across ten health systems in the United States. By using this unique and extensive dataset, Prenosis has been able to enhance the typical hospital clinical datasets by adding biological data, enabling the rapid development of a suite of AI diagnostics and precision therapeutics specifically tailored for acute care environments. The Sepsis ImmunoScore itself uses this dataset to categorize patients into four discrete risk stratification levels, providing clinicians with an actionable understanding of sepsis risk. This stratification aids in the early detection of sepsis and helps allocate medical resources more effectively, which is necessary for improving sepsis outcomes and reducing related healthcare costs.
Roche’s partnership with Prenosis goes beyond the mere technological innovation embodied in the Sepsis ImmunoScore. It represents a shared commitment to advancing healthcare through precision medicine and the ethical application of AI. The extensive market reach of Roche Diagnostics combined with the clinical utility of the Sepsis ImmunoScore promises to broaden access to this tool, enabling a greater number of hospitals and healthcare providers to implement it responsibly. This collaboration is poised to impact the healthcare landscape by enhancing the accuracy of sepsis diagnosis and streamlining clinical workflows. As both companies continue to leverage their respective strengths, Roche in diagnostic reach and regulatory compliance, and Prenosis in precision medicine and AI analytics, their partnership will allow future advancements in the urgent and ongoing fight against sepsis.
